NanoViricides, Inc. (NNVC) investor relations documents from the company's IR site: 2 presentations, 1 press release; latest deck 2025-11-08. Read in-app with summaries. First-party data.
https://www.nanoviricides.com/files/Presentations/2025-11-08%20NanoViricides%20-%20Annual%20Shareholder%20Meeting%20Pres: NanoViricides, Inc. (NYSE-Amer: NNVC) is a clinical-stage company developing broad-spectrum nanomedicines, with lead candidate NV-387 entering Phase II for MPox.
| Published | Type | Document |
|---|---|---|
| Press release | https://www.nanoviricides.com/Investor%20Info/2028-05-16%20NanoViricides%20Announces%20Closing%20of%20-2%20Million%20Reg | |
| 2025-11-08 | Presentation | https://www.nanoviricides.com/files/Presentations/2025-11-08%20NanoViricides%20-%20Annual%20Shareholder%20Meeting%20Pres |
| 2024-09-18 | Presentation | https://www.nanoviricides.com/files/News%20PDFs/2024-09-18%20NanoViricides%20Presentation%20-%20with%20Markets.pdf |
NNVC overview · NNVC earnings · NNVC financials · NNVC KPIs · NNVC ownership · NNVC peers · NNVC filings
Documents published by the company on its investor-relations site; summaries are model-written. Not personalized investment advice.